BLTE (Belite Bio) Ending Cash Position: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLTE Belite Bio Inc BLTE
21 GF Score
Price $151.57
! 3 Warning Signs
View Full Analysis

What is Belite Bio Ending Cash Position?

Belite Bio BLTE -3.87% 21 Ending Cash Position is $0.00 Mil as of Jun. 2026. GuruFocus rates BLTE with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Belite Bio's Ending Cash Position for the quarter that ended in Jun. 2026 was $0.00 Mil.

Belite Bio's annual Ending Cash Position declined from Dec. 2023 ($88.16 Mil) to Dec. 2024 ($31.68 Mil) but then increased from Dec. 2024 ($31.68 Mil) to Dec. 2025 ($352.93 Mil).

Belite Bio Ending Cash Position Related Terms

Belite Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Belite Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Ending Cash Position Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 17.34 42.09 88.16 31.68 352.93

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BLTE
21GF Score
Belite Bio Inc BLTE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Belite Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=31.677+321.255
=352.93

Belite Bio's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.00 Mil mean?
Belite Bio (BLTE) has a Ending Cash Position of $0.00 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Belite Bio and its competitors.
Is Belite Bio's Ending Cash Position too high?
Belite Bio's current Ending Cash Position is $0.00 Mil. Overall, Belite Bio has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Ending Cash Position compare to CGON and LGND?
Belite Bio's Ending Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Belite Bio and its competitors. Belite Bio's current Ending Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (BLTE) has a current Ending Cash Position of $0.00 Mil. The current Ending Cash Position is $0.00 Mil. Belite Bio's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Belite Bio (BLTE), the current Ending Cash Position is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belite Bio Business Description

Other Exchanges D01:Germany
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
21GF Score

Get the complete analysis for BLTE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$151.57
Price